Mechanisms that promote the evolution of cross-reactive antibodies upon vaccination with designed influenza immunogens
Author(s)
Yang, Leerang; Caradonna, Timothy M; Schmidt, Aaron G; Chakraborty, Arup K
DownloadPublished version (4.716Mb)
Publisher with Creative Commons License
Publisher with Creative Commons License
Creative Commons Attribution
Terms of use
Metadata
Show full item recordAbstract
Immunogens that elicit broadly neutralizing antibodies targeting the conserved receptor-binding site (RBS) on influenza hemagglutinin may serve as candidates for a universal influenza vaccine. Here, we develop a computational model to interrogate antibody evolution by affinity maturation after immunization with two types of immunogens: a heterotrimeric "chimera" hemagglutinin that is enriched for the RBS epitope relative to other B cell epitopes and a cocktail composed of three non-epitope-enriched homotrimers of the monomers that comprise the chimera. Experiments in mice find that the chimera outperforms the cocktail for eliciting RBS-directed antibodies. We show that this result follows from an interplay between how B cells engage these antigens and interact with diverse helper T cells and requires T cell-mediated selection of germinal center B cells to be a stringent constraint. Our results shed light on antibody evolution and highlight how immunogen design and T cells modulate vaccination outcomes.
Date issued
2023-03Department
Massachusetts Institute of Technology. Department of Chemical Engineering; Ragon Institute of MGH, MIT and Harvard; Massachusetts Institute of Technology. Department of Physics; Massachusetts Institute of Technology. Department of Chemistry; Massachusetts Institute of Technology. Institute for Medical Engineering & ScienceJournal
Cell Reports
Publisher
Elsevier BV
Citation
Yang, Leerang, Caradonna, Timothy M, Schmidt, Aaron G and Chakraborty, Arup K. 2023. "Mechanisms that promote the evolution of cross-reactive antibodies upon vaccination with designed influenza immunogens." Cell Reports, 42 (3).
Version: Final published version